Cargando…
Review of checkpoint immunotherapy for the management of non-small cell lung cancer
Checkpoint immunotherapy uses highly selective humanized monoclonal antibodies against checkpoint signals such as programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1). By blocking these receptors and signals, the immune system can be reactivated to fight the tumor. Immunoth...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074780/ https://www.ncbi.nlm.nih.gov/pubmed/30105218 http://dx.doi.org/10.2147/ITT.S125070 |
_version_ | 1783344486301040640 |
---|---|
author | Raju, Shine Joseph, Ranjit Sehgal, Sameep |
author_facet | Raju, Shine Joseph, Ranjit Sehgal, Sameep |
author_sort | Raju, Shine |
collection | PubMed |
description | Checkpoint immunotherapy uses highly selective humanized monoclonal antibodies against checkpoint signals such as programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1). By blocking these receptors and signals, the immune system can be reactivated to fight the tumor. Immunotherapy for advanced non-small cell lung cancer (NSCLC) has resulted in a new paradigm of treatment options resulting in improved survival and response rates and has a less severe yet unique toxicity profile when compared to chemotherapy. PD-1 inhibitors, nivolumab and pembrolizumab, and PD-L1 inhibitor, atezolizumab, are currently approved by regulatory authorities for the treatment of advanced NSCLC. This article provides a detailed review of these newer agents, their mechanism of action, side-effect profile, therapeutic indications and current evidence supporting their use in the management of NSCLC. |
format | Online Article Text |
id | pubmed-6074780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-60747802018-08-13 Review of checkpoint immunotherapy for the management of non-small cell lung cancer Raju, Shine Joseph, Ranjit Sehgal, Sameep Immunotargets Ther Review Checkpoint immunotherapy uses highly selective humanized monoclonal antibodies against checkpoint signals such as programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1). By blocking these receptors and signals, the immune system can be reactivated to fight the tumor. Immunotherapy for advanced non-small cell lung cancer (NSCLC) has resulted in a new paradigm of treatment options resulting in improved survival and response rates and has a less severe yet unique toxicity profile when compared to chemotherapy. PD-1 inhibitors, nivolumab and pembrolizumab, and PD-L1 inhibitor, atezolizumab, are currently approved by regulatory authorities for the treatment of advanced NSCLC. This article provides a detailed review of these newer agents, their mechanism of action, side-effect profile, therapeutic indications and current evidence supporting their use in the management of NSCLC. Dove Medical Press 2018-07-31 /pmc/articles/PMC6074780/ /pubmed/30105218 http://dx.doi.org/10.2147/ITT.S125070 Text en © 2018 Raju et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Raju, Shine Joseph, Ranjit Sehgal, Sameep Review of checkpoint immunotherapy for the management of non-small cell lung cancer |
title | Review of checkpoint immunotherapy for the management of non-small cell lung cancer |
title_full | Review of checkpoint immunotherapy for the management of non-small cell lung cancer |
title_fullStr | Review of checkpoint immunotherapy for the management of non-small cell lung cancer |
title_full_unstemmed | Review of checkpoint immunotherapy for the management of non-small cell lung cancer |
title_short | Review of checkpoint immunotherapy for the management of non-small cell lung cancer |
title_sort | review of checkpoint immunotherapy for the management of non-small cell lung cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6074780/ https://www.ncbi.nlm.nih.gov/pubmed/30105218 http://dx.doi.org/10.2147/ITT.S125070 |
work_keys_str_mv | AT rajushine reviewofcheckpointimmunotherapyforthemanagementofnonsmallcelllungcancer AT josephranjit reviewofcheckpointimmunotherapyforthemanagementofnonsmallcelllungcancer AT sehgalsameep reviewofcheckpointimmunotherapyforthemanagementofnonsmallcelllungcancer |